We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02574962
Recruitment Status : Withdrawn
First Posted : October 14, 2015
Last Update Posted : July 18, 2016
Information provided by (Responsible Party):
Mamatha Pasnoor, MD, University of Kansas Medical Center

Brief Summary:
The purpose of this pilot study is to assess the safety and efficacy of Acthar® Gel in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients.

Condition or disease Intervention/treatment Phase
Chronic Inflammatory Demyelinating Polyneuropathy Drug: H.P. Acthar® Gel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Study Start Date : August 2015
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2018

Arm Intervention/treatment
Experimental: Acthar® Gel
For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
Drug: H.P. Acthar® Gel
Other Names:
  • Acthar® Gel
  • repository corticotropin injection

Primary Outcome Measures :
  1. Number of Participants With Treatment-Related Adverse Events [ Time Frame: 28 Weeks ]
    Count of adverse events experienced by study participants.

Secondary Outcome Measures :
  1. Efficacy of study drug [ Time Frame: Change from Baseline to 28 Weeks ]
    Measured using the Inflammatory Neuropathy Cause and Treatment (INCAT) score. The INCAT scale has upper and lower extremity components (maximum of 5 points for upper (arm disability) and maximum of 5 points for lower (leg disability) that add up to a maximum of 10-points. A score of 0 indicates no problems. A score of 10 indicates person is severely incapacitated.

Other Outcome Measures:
  1. Maximum Grip Strength [ Time Frame: 28 weeks ]
    Measured by the amount of force a person uses to squeeze around a dynamometer.

  2. Manual Muscle Testing (MMT) [ Time Frame: 28 Weeks ]
    Measure based on the Medical Research Council (MRC) sum score (strength score combined for 12 specified muscle groups) on MMT.

  3. Rasch-built Overall Disability Scale (R-ODS) [ Time Frame: 28 Weeks ]
    The R-ODS is a questionnaire that rates a person's ability to perform 24 daily activities such as eating, using the toilet, taking a shower, dressing, walking, dancing, running, or standing. Scores range from 0-48 with 0 meaning they cannot perform any of the tasks and 48 meaning they can perform all of the tasks without any difficulty.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CIDP diagnosed according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010
  • Age > 18 years
  • Able to give written informed consent
  • Patient's signs and symptoms should not be better explained by another disease process
  • Patients can be on prednisone as long as there has been no dose change for 4 weeks from baseline
  • Patients can be on following drugs as long as there has been no change for 60 days from baseline visit including azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, intravenous immunoglobulin (IVIg) or other immunosuppressive drugs
  • INCAT score greater than or equal to 2

Exclusion Criteria:

  • Presence of any other causes of polyneuropathy or multifocal motor neuropathy, which in the opinion of the investigator is the major contributor to the numbness and weakness.
  • Other neurologic or orthopedic condition causing weakness
  • Treatment with plasma exchange (PLEX) within the last 30 days from baseline
  • Participation in another trial within the last 30 days from baseline or two ½ life of the drug being studied.
  • Latent tuberculosis or active infection
  • Contraindication per Acthar® Gel prescribing information scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history or presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction.
  • History of prior sensitivity to Acthar® Gel or other porcine products
  • Previous or present Infection with hepatitis C and hepatitis B
  • Pregnancy or nursing mothers.
  • Female subjects of childbearing potential either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or not sexually abstinent for the entire duration of the study, or not surgically sterile.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02574962

Layout table for location information
United States, Arizona
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
United States, California
University of Southern California
Los Angeles, California, United States, 90033
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Tennessee
Wesley Neurology Group
Memphis, Tennessee, United States, 38163
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05405
Sponsors and Collaborators
Mamatha Pasnoor, MD
Layout table for investigator information
Principal Investigator: Mamatha Pasnoor, MD University of Kansas Medical Center
Layout table for additonal information
Responsible Party: Mamatha Pasnoor, MD, Associate Professor, University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT02574962    
Other Study ID Numbers: STUDY00002770
First Posted: October 14, 2015    Key Record Dates
Last Update Posted: July 18, 2016
Last Verified: July 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Adrenocorticotropic Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs